SCHEMBL186201

SCHEMBL186201

CC(C)(C)OC(=O)C(C)(C(N)=O)C(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.46
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL600678 0.91 DGAT1 (0.56) DGAT1MAOAMAOB
SCHEMBL27771798 0.88 DGAT1 (0.41) DGAT1
SCHEMBL9784263 0.79 DGAT1 (0.58) DGAT1MAOAMAOB
SCHEMBL29908023 0.77 DGAT1 (0.44) DGAT1MAOAMAOB
SCHEMBL28714854 0.77 DGAT1 (0.44) DGAT1MAOAMAOB
SCHEMBL27747511 0.72 DGAT1 (0.50) DGAT1
SCHEMBL6687359 0.72 DGAT1 (0.50) DGAT1
SCHEMBL320271 0.72 DGAT1 (0.50) DGAT1
SCHEMBL22356150 0.72 DGAT1 (0.44) DGAT1MAOAMAOB
SCHEMBL307610 0.71 DGAT1 (0.55) DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8580746-B2 Amide linkage cyclic natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2013-11-12 US disclosed
US-8580747-B2 Cyclic natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2013-11-12 US disclosed
EP-2001518-B1 CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2013-07-10 EP disclosed
US-8114844-B2 Linear and cyclic melanocortin receptor-specific peptidomimetics PALATIN TECHNOLOGIES, INC. (US) 2012-02-14 US disclosed
EP-2004352-B1 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2012-01-04 EP disclosed
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates PALATIN TECHNOLOGIES, INC. (US) 2011-10-27 US disclosed
US-7964181-B2 Amino acid surrogates for peptidic constructs PALATIN TECHNOLOGIES, INC. (US) 2011-06-21 US disclosed
US-7795221-B2 Linear natriuretic peptide constructs PALATIN TECHNOLOGIES, INC. (US) 2010-09-14 US disclosed
US-20100075895-A1 Cyclic Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2010-03-25 US disclosed
US-20100035821-A1 Amide Linkage Cyclic Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2010-02-11 US disclosed
EP-2004633-A2 LINEAR NATRIURETIC PEPTIDE CONSTRUCTS Palatin Technologies, Inc. (US) 2008-12-24 EP disclosed
EP-2004352-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS Palatin Technologies, Inc. (US) 2008-12-24 EP disclosed
EP-2001518-A2 CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS Palatin Technologies, Inc. (US) 2008-12-17 EP disclosed
WO-2007115164-A9 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES INC (US) 2007-11-29 WO disclosed
US-20070265206-A1 Cyclic Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-15 US disclosed
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-11-08 US disclosed
WO-2007115182-A2 LINEAR NATRIURETIC PEPTIDE CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed
WO-2007115175-A2 CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed
WO-2007115164-A2 AMINO ACID SURROGATES FOR PEPTIDIC CONSTRUCTS PALATIN TECHNOLOGIES, INC. (US) 2007-10-11 WO disclosed
US-20070232546-A1 Linear Natriuretic Peptide Constructs PALATIN TECHNOLOGIES, INC. (US) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263818-A1 Peptidic Constructs with Amino Acid Surrogates ARGLU1, QRFPR, ARG1 DGAT1 4730/4885MAOA 3961/4885MAOB 3418/4885
US-20070265206-A1 Cyclic Natriuretic Peptide Constructs NPR1, NPR3, NPPA DGAT1 4797/4885MAOA 4145/4885MAOB 4261/4885
US-20070260040-A1 Amino Acid Surrogates for Peptidic Constructs ARGLU1, ARG1, QRFPR DGAT1 4761/4885MAOA 2074/4885MAOB 1519/4885
US-20100035821-A1 Amide Linkage Cyclic Natriuretic Peptide Constructs NPR1, NPR3, NPPA DGAT1 4204/4885MAOA 3726/4885MAOB 3771/4885
US-20070232546-A1 Linear Natriuretic Peptide Constructs NPR1, NPR3, NPPA DGAT1 4816/4885MAOA 3490/4885MAOB 3713/4885
US-20100075895-A1 Cyclic Natriuretic Peptide Constructs NPR1, NPR3, NPPA DGAT1 4797/4885MAOA 4145/4885MAOB 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.